This work compared the safety and efficacy of the culotte technique versus the use of self-expanding Biolimus A9 (AXXESS) eluting stent evaluating the healing of the vessel by OCT besides quantitative angiography and clinical events. In one, group (n = 20) bifurcated stent system AXXESS plus everolimus-eluting stents in the main distal branch and side...
NEXT Trial: Biodegradable polymer stent (Nobori) was similar to the permanent polymer stents (Xience / Promus) at 2 years.
This multicenter work from Japanrandomized 3200 patients to receive biodegradable polymer biolimus eluting stent(Nobori) or everolimus-eluting stent with permanent polymer (Xience / Promus). The primary end point for efficacy was any revascularizationlesion. A two year follow up the Nobori stent was non-inferior to death or myocardial infarction (7.83% versus 7.69%) and TLR (6.23% versus 5.95%). ...
COMFORTABLE AMI: A randomized trial comparing a coated stent with biodegradable biolimus polymer (Biomatrix) with an uncoated stent (Gazelle) in patients with AMI with ST segment elevation.
Randomized trial (n = 1161 patients in 16 centers) comparing a coated stent with biodegradable biolimus polymer (Biomatrix) versus uncoated stent (Gazelle) in patients with AMI with ST segment elevation. While there is no doubt about the effectiveness of first generation SF to reduce the rate of reoperations compared with non-drug eluting stents, there is...
NEXT trial looked at a non-inferiority degradable polymer stent versus a second-generation permanent polymer stent.
Previous studies of non-inferiority (SORT-OUT III and V) compared the biodegradable polymer biolimus-eluting stent (BES) with permanent polymer stent and sirolimus-eluting stent (SES) or everolimus-eluting stent (EES), showing no differences, although the data is still contradictory. The aim of this study was to evaluate whether the recently approved BES is not inferior to EES in...
IN-PACT CORO: OCT validation of drug-eluting balloons
Drug-eluting balloons could reduce intimal hyperplasia detected by OCT in intmerventions with conventional stents. 30 patients were randomized into 3 groups: 10 patients received conventional stents, 10 patients received a drug-eluting balloon prior to the conventional stent, and 10 patients receive a drug-eluting balloon after the conventional stent. We performed angiographic and OCT follow-up at...
BIOFLOW II. Stent eluidor de sirolimus com polímero degradável.
This non-inferiority design study compared the sirolimus-eluting stent with biodegradable polymer versus everolimus-eluting stent with permanent polymer in de novo coronary lesions. The primary endpoint was late lumen loss at nine months. We Included 440 patients with stable coronary lesions randomized 2:1 to receive the new sirolimus eluting stent with biodegradable polymer versus everolimus eluting...
TRYTON: Stent dedicated to bifurcations fails to demonstrate non-inferiority when compared with provisional
The aim of this study was to compare the results of stent TRYTON (non-drug eluting) in the side branch associated with the implantation of a drug-eluting stent in the main branch compared to the drug-eluting stent implantation in the main branch with provisional stent technique.704 patients were included with the intention of demonstrating non-inferiority versus...
Current hemodialysis patients show similar results for sirolimus-eluting and paclitaxel
Original title: Drug-eluting stents in patients on chronic haemodialysis: Paclitaxel-eluting stents vs. limus –eluting stents Reference: Gabriel l. Sardi, et al. Cardiovasc Revasc Med. 2014 Mar;15(2):86-91. End Stage Renal Disease (ESRD) including renal failure on hemodialysis is associated with coronary heart disease and diabetes with subsequent need for revascularization that in this special population has a high...
Angioplasty using a drug eluting balloon in the superficial femoral artery
Original title: Drug-Coated Balloon Versus Standard Percutaneous Transluminal Angioplasty for the Treatment of Superficial Femoral and Popliteal Peripheral Artery Disease 12-Month Results From the IN.PACT SFA Randomized Trial. Reference: Gunnar Tepe et al. Circulation. 2015;131:495-502. This interesting study randomly selected 331 patients with intermittent claudication or ischemic rest pain due to stenosis of the superficial femoral artery or...
Paclitaxel coated balloon catheter vs. DES for DES instent restenosis
Original title: Paclitaxel – coated balloon catheter compared with drug- eluting stent for drug-eluting stent restenosis in routine clinical practice. Reference: SeijiHabara et al.EuroIntervention 2015; 10-online publish-ahead-of-printFebruary 2015. The paclitaxel coated balloon catheter (PCB) is not inferior to DES for the treatment of instent restenosis (IRS). The aim of this study is to compare the efficacy of the...